Mustafa KULAKSIZOĞLU, Mustafa CAN, İlker ÇORDAN, Muhammet KOCABAŞ, Melia KARAKÖSE, Hatice ÇALIŞKAN BURGUCU, Feridun KARAKURT

Increased incidence of malignancy in patients with primary hyperparathyroidism

Background/aim: Primary hyperparathyroidism (PHPT) is a disease that is diagnosed more frequently and generally in the asymptomatic period, with widely available biochemical tests. Evidence suggesting an association between PHPT and malignancy risk is increasing. Clarification of this association will be useful in PHPT for malignancy screening and management of patients with PHPT. In this study, we aimed to investigate the frequency of cancer in PHPT patients. Materials and methods: A total of 775 PHPT patients were included in the retrospective study. Demographic, clinical and laboratory data of the patients were evaluated retrospectively. Results: Malignancy was detected in 128 (16.50%) of 775 PHPT patients (female/male: 625/150). The mean age at diagnosis of PHPT was 57.99 ± 10.86 years, and the mean age at diagnosis of malignancy was 57.46 ± 11.17 years. Of the 128 patients with malignancy, 53 (41.40%) were diagnosed in the same year as PHPT. In terms of malignancy types, 51 (6.50%) of 775 PHPT patients had thyroid cancer. Thyroid cancer was followed by breast cancer (2.30%) and stomach cancer (1%) in order of frequency. Conclusion: We think that PHPT patients should be examined more carefully in terms of cancer risk, especially thyroid cancer. More comprehensive studies are needed to clarify the relationship between PHPT and cancer.Key words: Primary hyperparathyroidism, cancer, thyroid cancer

PDF

___

1. Silverberg SJ, Bilezikian JP. Asymptomatic primary hyperparathyroidism: a medical perspective. Surgical Clinics of North America 2004; 84 (3): 787-801. doi: 10.1016/j. suc.2004.03.002
2. Walker MD, Silverberg SJ. Primary hyperparathyroidism. Nature Reviews Endocrinology 2018; 14 (2): 115-125. doi: 10.1038/nrendo.2017.104
3. Silverberg SJ, Shane E, Jacobs TP, Siris E, Bilezikian JP. A 10- year prospective study of primary hyperparathyroidism with or without parathyroid surgery. New England Journal of Medicine 1999; 341 (17): 1249-1255. doi: 10.1056/NEJM199910213411701
4. Palmieri S, Roggero L, Cairoli E, Morelli V, Scillitani A et al. Occurrence of malignant neoplasia in patients with primary hyperparathyroidism. European Journal of Internal Medicine 2017; 43: 77-82. doi: 10.1016/j.ejim.2017.06.001
5. Nilsson IL, Zedenius J, Yin L, Ekbom A. The association between primary hyperparathyroidism and malignancy: nationwide cohort analysis on cancer incidence after parathyroidectomy. Endocrine-Related Cancer 2007; 14 (1): 135-40. doi: 10.1677/ erc.1.01261
6. Palmér M, Adami HO, Krusemo UB, Ljunghall S. Increased risk of malignant diseases after surgery for primary hyperparathyroidism. A nationwide cohort study. American Journal of Epidemiology 1988; 127 (5): 1031-1040. doi: 10.1093/oxfordjournals.aje.a114879
7. Ghosh S, Collier A, Clark D, Elhadd T, Malik I. Primary hyperparathyroidism (Nationwide cohort study): an increased risk of cancer and decreased survival. In: 11th European Congress of Endocrinology. İstanbul, Turkey.
8. Fedorak IJ, Salti G, Fulton N, Schark C, Straus FH 2nd et al. Increased incidence of thyroid cancer in patients with primary hyperparathyroidism: a continuing dilemma. American Surgeon 1994; 60 (6): 427-431
9. Kösem M, Algün E, Kotan C, Harman M, Oztürk M. Coexistent thyroid pathologies and high rate of papillary cancer in patients with primary hyperparathyroidism: controversies about minimal invasive parathyroid surgery. Acta Chirurgica Belgica 2004; 104 (5): 568-571. doi: 10.1080/00015458.2004.11679616
10. Kutlutürk K, Otan E, Yağcı MA, Usta S, Aydın C et al. Thyroid pathologies accompanying primary hyperparathyroidism: a high rate of papillary thyroid microcarcinoma. Ulusal Cerrahi Dergisi 2014; 30 (3): 125-128. doi: 10.5152/UCD.2014.2685
11. Palmér M, Adami HO, Krusemo UB, Ljunghall S. Increased risk of malignant diseases after surgery for primary hyperparathyroidism. A nationwide cohort study. American Journal of Epidemiology 1988; 127 (5): 1031-1040. doi: 10.1093/oxfordjournals.aje.a114879
12. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer Journal for Clinicians 2018; 68 (6): 394-424. doi: 10.3322/caac.21492
13. Cuhaci N, Ozdemir D, Polat B, Arpacı D, Yıldırım N et al. Concomitant thyroid lesions in patients with primary hyperparathyroidism. Asian Journal of Surgery 2017; 40 (5): 338-344. doi: 10.1016/j.asjsur.2015.10.006
14. Gates JD, Benavides LC, Shriver CD, Peoples GE, Stojadinovic A. Preoperative thyroid ultrasound in all patients undergoing parathyroidectomy? Journal of Surgical Research 2009; 155 (2): 254-260. doi: 10.1016/j.jss.2008.09.012
15. Morita SY, Somervell H, Umbricht CB, Dackiw AP, Zeiger MA. Evaluation for concomitant thyroid nodules and primary hyperparathyroidism in patients undergoing parathyroidectomy or thyroidectomy. Surgery 2008; 144 (6): 862-866; discussion 866-8. doi: 10.1016/j.surg.2008.07.029
16. Arciero CA, Shiue ZS, Gates JD, Peoples GE, Dackiw AP et al. Preoperative thyroid ultrasound is indicated in patients undergoing parathyroidectomy for primary hyperparathyroidism. Journal of Cancer 2012; 3: 1-6. doi: 10.7150/jca.3.1
17. Beus KS, Stack BC Jr. Synchronous thyroid pathology in patients presenting with primary hyperparathyroidism. American Journal of Otolaryngology 2004; 25 (5): 308-312. doi: 10.1016/j.amjoto.2004.03.006
18. Lehwald N, Cupisti K, Krausch M, Ahrazoglu M, Raffel A et al. Coincidence of primary hyperparathyroidism and nonmedullary thyroid carcinoma. Hormone and Metabolic Research 2013; 45 (9): 660-663. doi: 10.1055/s-0033-1345184
19. Zheng YX, Xu SM, Wang P, Chen L. Preoperative localization and minimally invasive management of primary hyperparathyroidism concomitant with thyroid disease. Journal of Zhejiang University Science B: Biomedicine & Biotechnology 2007; 8 (9): 626-631. doi: 10.1631/jzus.2007. B0626
20. Hollenbeak CS, Lendel I, Beus KS, Ruda JM, Stack BC Jr. The cost of screening for synchronous thyroid disease in patients presenting with primary hyperparathyroidism. Archives of OtolaryngologyHead & Neck Surgery 2007; 133 (10): 1013- 1021. doi: 10.1001/archotol.133.10.1013
21. Preda C, Branisteanu D, Armasu I, Danila R, Velicescu C et al. Coexistent papillary thyroid carcinoma diagnosed in surgically treated patients for primary versus secondary hyperparathyroidism: same incidence, different characteristics. BMC Surgery 2019; 19 (1): 94. doi: 10.1186/s12893-019-0556-y
22. Seehofer D, Rayes N, Klupp J, Nüssler NC, Ulrich F et al. Prevalence of thyroid nodules and carcinomas in patients operated on for renal hyperparathyroidism: experience with 339 consecutive patients and review of the literature. World Journal of Surgery 2005; 29 (9): 1180-1184. doi: 10.1007/ s00268-005-7859-0
23. LiVolsi VA, Feind CR. Parathyroid adenoma and nonmedullary thyroid carcinoma. Cancer 1976; 38 (3): 1391-1393. doi: 10.1002/1097-0142(197609)38:3<1391::aidcncr2820380344>3.0.co;2-c
24. Prinz RA, Barbato AL, Braithwaite SS, Brooks MH, Lawrence AM et al. Prior irradiation and the development of coexistent differentiated thyroid cancer and hyperparathyroidism. Cancer 1982; 49 (5): 874- 877. doi: 10.1002/1097-0142(19820301)49:5<874::aidcncr2820490509>3.0.co;2-d
25. Nishiyama RH, Farhi D, Thompson NW. Radiation exposure and the simultaneous occurrence of primary hyperparathyroidism and thyroid nodules. Surgical Clinics of North America 1979; 59 (1): 65-75. doi: 10.1016/s0039-6109(16)41733-0
26. Burmeister LA, Sandberg M, Carty SE, Watson CG. Thyroid carcinoma found at parathyroidectomy: association with primary, secondary, and tertiary hyperparathyroidism. Cancer 1997; 79 (8): 1611-1616. doi: 10.1002/(sici)1097- 0142(19970415)79:8<1611::aid-cncr26>3.0.co;2-#
27. Pickard AL, Gridley G, Mellemkjae L, Johansen C, KofoedEnevoldsen A et al. Hyperparathyroidism and subsequent cancer risk in Denmark. Cancer 2002; 95 (8): 1611-1617. doi: 10.1002/cncr.10846